Carnitine Supplementation in Type 2 Diabetic Patients
Status:
Completed
Trial end date:
2019-11-11
Target enrollment:
Participant gender:
Summary
the results from animal studies and preliminary human studies show that carnitine
availability and acetylcarnitine concentrations are low in insulin resistant states such as
with type 2 diabetes mellitus. However, in humans, carnitine supplementation is sometimes
beneficial, but not in everyone. We hypothesize that this variability in response might be
due to differences between individuals in the amount of carnitine in the muscle i.e. subjects
with a low initial carnitine status will benefit more from supplementation. The state of the
art non-invasive magnetic resonance spectroscopy method allows us to identify patients muscle
acetylcarnitine status. Here we aim to test whether carnitine improves insulin sensitivity,
furthermore, whether acetylcarnitine concentration at baseline or other characteristics are
associated with the response (in insulin sensitivity) to carnitine supplementation.
Furthermore, we will examine the potentially positive effect of carnitine supplementation in
type 2 diabetes patients on intrahepatic lipid content, acetylcarnitine formation, blood
plasma metabolites, body composition, physical performance and quality of life